This Frontier presents the recent development of photoresponsive Ru-containing polymers for cancer treatment. These novel Ru-containing polymers are prepared by introducing photoresponsive Ru complexes into polymers. Based on their chemical structures in aqueous solutions, these polymers can selfassemble into different nanostructures. The self-assembled nanostructures can circulate in the blood stream, accumulate at tumor tissue, and can be taken up by tumor cells. Red light, which can penetrate into tissue deeply, can induce the photodissociation of these polymers and sensitize singlet oxygen ( 1 O 2 ) generation. Both dissociated Ru complexes and generated 1 O 2 can inhibit the growth of tumor cells.
Introduction
The design of new drugs for cancer treatment has been a major aspect in fundamental research. 1, 2 Metallodrugs play a vital role in this field. It is well known that the platinum complex, cisplatin, is the first US Food and Drug Administration (FDA) approved anticancer drug, which has been effectively used in clinics. [2] [3] [4] However, cisplatin has side effects and suffers from drug resistance, which motivated researchers to develop new metallodrugs. 5 As analogues of cisplatin, ruthenium (Ru) complexes are one of the good alternatives. 1, 2 To date, a large number of Ru complexes, which exhibit anticancer activities, have been designed. 1, 2, 6 After uptake by cancer cells, Ru complexes can bind with DNA, which effectively block DNA and RNA synthesis, leading to programmed cell death. [6] [7] [8] The increasing interest in Ru complexes is also due to their appealing photoresponsive properties. 2, [9] [10] [11] [12] Some Ru complexes can generate singlet oxygen under light irradiation, which enables them to be photosensitizers for photodynamic therapy (PDT). 10, [13] [14] [15] In addition, light can uncage toxic Ru species or ligands from some Ru complexes for photoactivated chemotherapy (PACT). 9, 10 Therefore, some Ru complexes may be applied to combined PDT and PACT. We call them "phototherapy" in general in this Frontier.
The use of photoresponsive Ru complexes for anticancer phototherapy has attracted increasing attention because combined PDT and PACT can improve therapeutic efficiency.
1,2,9,10,13-15 The processes of using Ru complexes for phototherapy are similar to those of other photosensitive anticancer agents, such as photosensitizers or photoactivated ( pro)drugs for PDT or PACT. 16, 17 First, photosensitive anticancer agents (e.g., Ru complexes) should be injected into the blood vessel. Then, the agents with appropriate properties could accumulate at the tumor site through blood circulation and internalize into cancer cells. Light irradiation at the tumor site will activate the Ru complexes to generate toxic species, and consequently, inhibit tumor growth.
Deep-tissue photoactivation of Ru complexes with red light
Light penetration into tissue is one of the preconditions for phototherapy. 18 Many photoresponsive compounds, such as, o-nitrobenzyl, pyrene, and coumarin, have been studied and proposed for phototherapy. 18, 19 However, they are responsive to UV light or short wavelength visible light, which cannot penetrate deeply into tissue. In comparison, photoresponsive Ru complexes are promising for deep-tissue phototherapy because some of them are sensitive to red or near infrared (NIR) light in the "therapeutic window" (e.g., 650-900 nm). 2, 16, 20 For example, our group synthesized four photoresponsive Ru complexes and studied the photoactivation of these complexes in deep tissue. 21 Two of them (Ru3 and Ru4) have absorption tails in the "therapeutic window" and can be activated using red light (Fig. 1a) . We demonstrated that 671 nm red light can activate Ru3 and Ru4 after passing through a 16 mm-thick tissue ( Fig. 1b and c) . Additionally, activated Ru4 caused the inhibition of cancer cells. These results suggested that red-light-responsive Ru complexes (e.g., Ru3 and Ru4) are promising for deep-tissue phototherapy. Photoresponsive Ru complexes are considered as promising agents for phototherapy and have been widely used in vitro. 17 However, photoresponsive
Ru complexes are problematic for in vivo applications. First, Ru complexes display poor bioavailability for cancer treatment. They can be rapidly cleared from the bloodstream, leading to inefficient accumulation at tumor sites. 22 This problem could result in low therapeutic efficiency. Second, similar to other anticancer agents, Ru complexes may also cause serious toxic side effects on healthy tissues. 1 Thus, improving the therapeutic efficiency of photoresponsive Ru complexes and reducing their side effects are currently two challenging problems.
Photoresponsive Ru-containing polymers
To overcome the above-mentioned problems of low molecular weight Ru complexes, we designed Ru-containing block copolymers (BCPs) that could self-assemble into nanostructures in aqueous solutions. 23, 24 The combined PDT and PACT showed enhanced anticancer activity. The cell viability decreased to 24%, 75% and 80% when cells were incubated with micelles, vesicles and large compounds, followed by 656 nm red light irradiation. The anticancer performance of micelles was better than those of vesicles and large compound micelles due to their more efficient cellular uptake. Moreover, under the dark conditions, there was no cleavage of the Ru complex from the BCP assemblies, suggesting that no side effect would occur in a normal microenvironment. We also introduced Ru complexes into the main-chain of a BCP (Fig. 3) . 24 PolyRu is an ABA-type triblock copolymer that contains a hydrophobic and photolytic Ru-containing block and two hydrophilic and biocompatible PEG blocks (Fig. 3) . The weight fraction of the Ru-containing block in PolyRu was more than 50%, demonstrating an efficient drug-loading capacity of the BCP. In an aqueous solution, PolyRu selfassembled into nanoparticles with an average diameter of 180 nm. The PolyRu nanoparticles could be effectively taken up by the cancer cells including HeLa, PC3, and HepG2. The photodegradation of PolyRu induced by 656 nm red light facilitated the release of anticancer Ru complexes, and consequently, the proliferation of cancer cells was efficiently inhibited. More importantly, in vivo experiments in a mouse model demonstrated that Ru-containing BCPs could accumulate at tumor sites and inhibit the growth of tumor under light irradiation. In addition, the nanoparticles did not cause any pathological tissue damage/abnormality during the treatment. Thus, phototherapy using Ru-containing BCPs eliminated systemic toxicity caused by Ru complexes in vivo.
Conclusions and outlook
In conclusion, photoresponsive Ru-containing BCPs have been developed for anticancer phototherapy. These BCPs selfassembled into nanoparticles which could circulate in the blood stream, accumulate at tumor tissue, and inhibit the growth of cancer cells under red-light irradiation. Both the released toxic Ru complexes and generated 1 O 2 exhibit the anticancer effect. More importantly, Ru-containing nanoparticles can improve the bioavailability of Ru complexes and reduce their toxic side effects in vivo. The design strategies described here can be used to develop new and improved Rucontaining polymers for anticancer phototherapy. The studies using photoresponsive Ru-containing polymers for biomedical applications have just started. There are some open questions and challenges regarding their synthesis, characterization, and applications. This field still awaits more exploration. First, from the chemistry point of view, finding ways to synthesize photoresponsive Ru-containing polymers with controlled molecular weights and architecture is a challenge. In our work, we either grafted Ru complexes to polymers (Fig. 2) or used polycondensation to polymerize Ru-containing monomers (Fig. 3) . The "graft-to" method can only functionalize a part of the repeat units on the polymers. Polycondensation is difficult to control the molecular weight. Photo-responsive Rucontaining polymers, which are directly polymerized using controlled polymerization, have not been demonstrated.
Second, from the characterization point of view, it is difficult to analyze photoresponsive Ru-containing polymers using standard polymer analytical methods such as gel permeation chromatography (GPC) and static light scattering (SLS). The presence of charged moieties in such polymers may result in unreliable molecular weight characterization via GPC due to their interaction with the GPC column material. 27 The measurement using SLS is also difficult because the light irradiation of the sample with an inappropriate wavelength may cause the dissociation of the polymers. Suitable characterization methods to analyze such polymers are expected to be conducted. Third, from the therapeutic point of view, the anticancer efficiency of responsive Ru complexes needs further improvement. The Ru complexes used in the reported systems only demonstrated acceptable toxicity, which results in the moderate anticancer efficiency of these Ru-containing polymers. Developing polymers using high toxicity photoresponsive Ru complexes will help us improve the therapeutic efficacy of Rucontaining polymers.
Fourth, the activation wavelength of Ru-containing polymers needs to be further red-shifted. The best activation wavelength is at the NIR region. However, the absorption tails but not the peaks of the reported compounds just reach the NIR region. Although the two-photon process 28, 29 and upconversion-assisted photochemistry 18, [30] [31] [32] [33] [34] [35] [36] [37] [38] can activate Ru complexes using NIR light, both methods are based on inefficient nonlinear optical processes. Two-photon absorption requires unsafe high-intensity laser excitation and only occurs at the focus of pulsed lasers. Thus, two-photon absorption is not suited for phototherapy applications. Upconversion-assisted photoactivation often requires a laser intensity of at least several hundred mW cm −2 . Because light intensity decreases dramatically after passing through tissue (Fig. 1c) , upconversion is problematic for deep-tissue applications. Thus, the direct red-shift of the activation wavelength of Ru-containing polymers to the NIR region is more promising for deep-tissue applications. For example, the use of fluorinated aromatic rings or compounds with high aromaticity may help to red shift the activation wavelength. Such Ru-containing polymers could be sensitive to low-intensity NIR light, which is suited for phototherapy in real applications.
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